Organogenesis Holdings (ORGO) Change in Accured Expenses (2016 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Change in Accured Expenses of $293000.0 for Q1 2026, up 103.67% year-over-year from $143863.2 in Q1 2025, and down 96.71% quarter-over-quarter from $8.9 million in Q4 2025.
Organogenesis Holdings (ORGO) Change in Accured Expenses (2016 - 2026) Analysis & Trends
Organogenesis Holdings' Change in Accured Expenses history runs 11 years deep, the most recent figure standing at $293000.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 103.67% year-over-year to $293000.0; the TTM figure through Mar 2026 stood at $18.7 million (up 198.02% YoY), while the FY2025 annual figure was $10.4 million, up 1077.5% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $293000.0, down from $8.9 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $10.0 million in Q1 2024, with the low at -$9.9 million in Q2 2024.
- The 5-year median for Change in Accured Expenses is $23000.0 (2023), against an average of -$126294.1.
- Peak annual rise in Change in Accured Expenses reached 45309.09% in 2024, while the deepest fall reached 22180.0% in 2024.
- Organogenesis Holdings' Change in Accured Expenses stood at -$7.8 million in 2022, then soared by 100.3% to $23000.0 in 2023, then sank by 5065.22% to -$1.1 million in 2024, then soared by 880.65% to $8.9 million in 2025, then tumbled by 96.71% to $293000.0 in 2026.
- Business Quant data shows ORGO's Change in Accured Expenses at $293000.0 in Q1 2026, $8.9 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Organogenesis Holdings | 238.16 Mn | 191.32 Mn | 20.08 Mn | -9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.80 Mn |
| Jun 30, 2026 | -9.80 Mn |
| Mar 31, 2026 | 293,000.00 |
| Mar 31, 2026 | 293,000.00 |
| Dec 31, 2025 | 8.92 Mn |
| Dec 31, 2025 | 8.92 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.43 Mn |
| Jun 30, 2025 | 8.03 Mn |
| Jun 30, 2025 | 8.03 Mn |
| Mar 31, 2025 | -7.99 Mn |
| Mar 31, 2025 | -7.99 Mn |
| Dec 31, 2024 | -1.14 Mn |
| Dec 31, 2024 | -1.14 Mn |
| Sep 30, 2024 | 26,000.00 |
| Sep 30, 2024 | 26,000.00 |
| Jun 30, 2024 | -9.94 Mn |
| Jun 30, 2024 | -9.94 Mn |
| Mar 31, 2024 | 9.99 Mn |
| Mar 31, 2024 | 9.99 Mn |